OpGen - Spezialist gegen antibiotikaresistente Infektionen (Seite 11)
eröffnet am 13.08.15 09:48:54 von
neuester Beitrag 10.11.23 14:21:39 von
neuester Beitrag 10.11.23 14:21:39 von
Beiträge: 402
ID: 1.217.076
ID: 1.217.076
Aufrufe heute: 0
Gesamt: 36.933
Gesamt: 36.933
Aktive User: 0
ISIN: US68373L4068 · WKN: A3D38S · Symbol: 650
0,4620
EUR
0,00 %
0,0000 EUR
Letzter Kurs 26.04.24 Stuttgart
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,8660 | +44,27 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ihr seid wohl alle ausgestiegen. Soweit ich weiß ist hier ein großer Investor eingestiegen, was eigentlich positiv zu werten ist.
Irgendetwas ändert sich hier gerade. Werden die Aktien verändert? Wird das Unternehmen privatisiert?
Antwort auf Beitrag Nr.: 65.821.581 von Erdman am 24.11.20 12:04:13
OpGen’s subsidiary Curetis GmbH obtained CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.
The subsidiary Ares Genetics GmbH won the Austrian national digitization award and was also nominated for the 40th Austrian Innovation Award for its artificial intelligence powered, next-generation sequencing based molecular antibiotic susceptibility test marketed under the brand name ARESupa – Universal Pathogenome Assay.
Curetis GmbH was awarded EUR 350 thousand in non-dilutive grant funding in a collaboration project with InfectoGnostics campus at Jena University Hospital.
OpGen announced the award of a German Federal Government grant to its subsidiary, Curetis GmbH, and collaborators Carpegen GmbH and the Clinic for Small Animal Internal Medicine of the LMU Ludwig-Maximilians University to collaborate on a project focused on travel related and enteric diseases in small animals.
Ares Genetics GmbH in collaboration with researchers from the Johns Hopkins University School of Medicine, announced the publishing of a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.
OpGen announced the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.
OpGen itselfs successfully completed its study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients and data on the Unyvero HPN Panel was presented by the Karolinska investigators at ECCVID 2020.
The German Federal Ministry for Economic Affairs and Energy (BMWi) concluded its investigation of the OpGen business combination with Curetis with regards to its impact on the public order and security of the Federal Republic of Germany as well as national healthcare interests in the light of the current COVID-19 pandemic. No further action is expected from the Federal government on this matter.
... und Positives dazu (Hoffnungen)
Accomplishment of the following key milestones in the third quarter of 2020 and year to date:OpGen’s subsidiary Curetis GmbH obtained CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.
The subsidiary Ares Genetics GmbH won the Austrian national digitization award and was also nominated for the 40th Austrian Innovation Award for its artificial intelligence powered, next-generation sequencing based molecular antibiotic susceptibility test marketed under the brand name ARESupa – Universal Pathogenome Assay.
Curetis GmbH was awarded EUR 350 thousand in non-dilutive grant funding in a collaboration project with InfectoGnostics campus at Jena University Hospital.
OpGen announced the award of a German Federal Government grant to its subsidiary, Curetis GmbH, and collaborators Carpegen GmbH and the Clinic for Small Animal Internal Medicine of the LMU Ludwig-Maximilians University to collaborate on a project focused on travel related and enteric diseases in small animals.
Ares Genetics GmbH in collaboration with researchers from the Johns Hopkins University School of Medicine, announced the publishing of a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.
OpGen announced the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.
OpGen itselfs successfully completed its study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients and data on the Unyvero HPN Panel was presented by the Karolinska investigators at ECCVID 2020.
The German Federal Ministry for Economic Affairs and Energy (BMWi) concluded its investigation of the OpGen business combination with Curetis with regards to its impact on the public order and security of the Federal Republic of Germany as well as national healthcare interests in the light of the current COVID-19 pandemic. No further action is expected from the Federal government on this matter.
OpGen has discontinued Acuitas AMR Gene Panel (urine) clinical trial
and will discontinue FISH product line globally by mid-2021
Total Revenue for Q3 2020 was approximately $1.1 million dollars
Operating expenses for the third quarter of 2020 were $7.2 million,
compared with $4.1 million in the third quarter of 2019
The net loss for the third quarter of 2020 was $7.7 million or $0.40 per share,
compared with $3.5 million or $3.95 per share in the third quarter of 2019
Cash and cash equivalents were $10.5 million as of September 30, 2020.
Da ist wohl bald die nächste Kapitalerhöhung notwendig, oder ein neuer Investor steigt ein.
Ob der den aktuellen Kurs bezahlt erscheint mir fraglich.
and will discontinue FISH product line globally by mid-2021
Total Revenue for Q3 2020 was approximately $1.1 million dollars
Operating expenses for the third quarter of 2020 were $7.2 million,
compared with $4.1 million in the third quarter of 2019
The net loss for the third quarter of 2020 was $7.7 million or $0.40 per share,
compared with $3.5 million or $3.95 per share in the third quarter of 2019
Cash and cash equivalents were $10.5 million as of September 30, 2020.
Da ist wohl bald die nächste Kapitalerhöhung notwendig, oder ein neuer Investor steigt ein.
Ob der den aktuellen Kurs bezahlt erscheint mir fraglich.
Trading Spotlight
Das Unternehmen der OpGen-Gruppe, Ares Genetics, führt kommerziell einen NGS-basierten Antibiotikaresistenz-Testdienst für native Proben ein und erhält einen Großauftrag von der Public Health Agency
http://ir.opgen.com/news-releases/news-release-details/opgen…
http://ir.opgen.com/news-releases/news-release-details/opgen…
Was für ein Kursziel hast du eigentlich vor Augen? :-)
Wann wird das ganze endlich mal im steigende Notierungen wiedergespiegelt? (der Short Quota hat sich inzwischen drastisch reduziert 
)
OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudited Revenue and Cash Position for the Third Quarter 2020
The company also announced accomplishment of the following key milestones in the third quarter of 2020 and year to date:
OpGen’s subsidiary Curetis GmbH obtained CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.
OpGen announced that subsidiary Ares Genetics GmbH won the Austrian national digitization award and was also nominated for the 40th Austrian Innovation Award for its artificial intelligence powered, next-generation sequencing based molecular antibiotic susceptibility test marketed under the brand name ARESupa – Universal Pathogenome Assay.
OpGen’s subsidiary Curetis GmbH received EUR 350 thousand in grant funding in a collaboration project with InfectoGnostics campus at Jena University Hospital.
OpGen’s subsidiary Ares Genetics GmbH in collaboration with researchers from the Johns Hopkins University School of Medicine, announced the publishing of a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.
OpGen announced the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.
OpGen successfully completed its study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients and data on the Unyvero HPN Panel was presented by the Karolinska investigators at ECCVID 2020.
OpGen significantly improved its working capital position in the third quarter of 2020 through the sale of approximately 1.8 million shares of common stock under the company’s ATM program and the exercise of warrants from the October 2019 financing for gross proceeds of $4.4 million during the third quarter. During the nine months ended September 30, 2020, the Company sold approximately 11.4 million shares of common stock under the company’s ATM program and upon exercise of warrants from the October 2019 offering for gross proceeds of $24.4 million.
The German Federal Ministry for Economic Affairs and Energy (BMWi) concluded its investigation of the OpGen business combination with Curetis with regards to its impact on the public order and security of the Federal Republic of Germany as well as national healthcare interests in the light of the current COVID-19 pandemic. No further action is expected from the Federal government on this matter.
https://www.globenewswire.com/news-release/2020/10/15/210908…
Ich hab das Gefühl -(allerdings wie oft zuvor)- "nicht mehr sooooo lange" 🤢
)OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudited Revenue and Cash Position for the Third Quarter 2020
The company also announced accomplishment of the following key milestones in the third quarter of 2020 and year to date:
OpGen’s subsidiary Curetis GmbH obtained CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.
OpGen announced that subsidiary Ares Genetics GmbH won the Austrian national digitization award and was also nominated for the 40th Austrian Innovation Award for its artificial intelligence powered, next-generation sequencing based molecular antibiotic susceptibility test marketed under the brand name ARESupa – Universal Pathogenome Assay.
OpGen’s subsidiary Curetis GmbH received EUR 350 thousand in grant funding in a collaboration project with InfectoGnostics campus at Jena University Hospital.
OpGen’s subsidiary Ares Genetics GmbH in collaboration with researchers from the Johns Hopkins University School of Medicine, announced the publishing of a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.
OpGen announced the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.
OpGen successfully completed its study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients and data on the Unyvero HPN Panel was presented by the Karolinska investigators at ECCVID 2020.
OpGen significantly improved its working capital position in the third quarter of 2020 through the sale of approximately 1.8 million shares of common stock under the company’s ATM program and the exercise of warrants from the October 2019 financing for gross proceeds of $4.4 million during the third quarter. During the nine months ended September 30, 2020, the Company sold approximately 11.4 million shares of common stock under the company’s ATM program and upon exercise of warrants from the October 2019 offering for gross proceeds of $24.4 million.
The German Federal Ministry for Economic Affairs and Energy (BMWi) concluded its investigation of the OpGen business combination with Curetis with regards to its impact on the public order and security of the Federal Republic of Germany as well as national healthcare interests in the light of the current COVID-19 pandemic. No further action is expected from the Federal government on this matter.
https://www.globenewswire.com/news-release/2020/10/15/210908…
Ich hab das Gefühl -(allerdings wie oft zuvor)- "nicht mehr sooooo lange" 🤢
Antwort auf Beitrag Nr.: 65.379.570 von Secondjob am 14.10.20 09:43:00der Kurs wird KE bereinigt angezeigt. Je mehr KEs es gab desto astronomischer wird der Anfangskurs. Vorteil dieser Variante ist die direkte Sichtbarkeit des historischen Cashburn.
Antwort auf Beitrag Nr.: 65.290.337 von Secondjob am 05.10.20 23:52:20
Weiß hierzu jemand eine Antwort?
Zitat von Secondjob: Was ist eigentlich mit dem Aktienkurs vor etwa 1 1/2 Jahren passiert? Waren das Kapitalerhöhungen? Stand diese Aktie tatsächlich mal bei 600 €?
Weiß hierzu jemand eine Antwort?
Durchsuchen
